

2. Hart GJ, Orr DC, Penn CR, Figueiredo HT, Gray NM, Boehme RE, et al. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. *Antimicrob Agents Chemother*. 1992;36:1688–94. <http://dx.doi.org/10.1128/AAC.36.8.1688>
3. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus replication *Sci Transl Med*. 2013;5:190ra79. doi: 10.1126/scitranslmed.3005471.
4. Schinazi RF. Assessment of the relative potency of emtricitabine and lamivudine. *J Acquir Immune Defic Syndr*. 2003;34:243–5, author reply 5–6. <http://dx.doi.org/10.1097/00126334-200310010-00017>
5. Kruining J, Heijtkink RA, Schalm SW. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. *J Hepatol*. 1995;22:263–7. [http://dx.doi.org/10.1016/0168-8278\(95\)80277-0](http://dx.doi.org/10.1016/0168-8278(95)80277-0)
6. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. *Proc Natl Acad Sci U S A*. 1986;83:8333–7. <http://dx.doi.org/10.1073/pnas.83.21.8333>

Address for correspondence: Peter B. Jahrling, Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, B8200 Research Plaza Dr, Frederick, MD 21702, USA; email: jahrlingp@niaid.nih.gov

Correction: Vol. 21, No. 2

The abbreviation mL was inadvertently used in the place of μ L in paragraphs 2 and 4 of the print edition of the article Potential Sexual Transmission of Zika Virus

(D. Musso et al.) The article is correct online (http://wwwnc.cdc.gov/eid/article/21/2/14-1363_article.htm)

**SEARCH PAST ISSUES OF EID
AT WWWNC.CDC.GOV/EID**